Peter Savas

Peter Savas serves as the CEO and Chairman of LikeMinds, a Boston-based company focused on dopamine transporter (DAT) imaging, where the team previously developed Neupro®, a groundbreaking transdermal drug for movement disorders. Additionally, Peter holds the position of Chair of the National Research Board at the Kennedy Krieger Institute, which specializes in pediatric neurological disorders, and serves as a Regional Council Board Member at Syracuse University, involved in advisory and development activities. From January 2016 to January 2018, Peter was the Director at Aerin Medical, a company focused on nasal obstructions. Peter Savas holds a BA in Chemistry, Organization & Management from Syracuse University and has earned an Advanced Professional Director Certification from the American College of Corporate Directors.